Detalles de la búsqueda
1.
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.
Ann Oncol
; 33(12): 1250-1268, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36228963
2.
Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer.
Ann Oncol
; 22(5): 1094-1101, 2011 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-21084429
3.
Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.
J Clin Oncol
; 18(7): 1399-411, 2000 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-10735887
4.
Exemestane improves survival compared with megoestrol acetate in postmenopausal patients with advanced breast cancer who have failed on tamoxifen. results Of a double-blind randomised phase III trial.
Eur J Cancer
; 36 Suppl 4: S86-7, 2000 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-11056333
5.
Exemestane improves survival in metastatic breast cancer: results of a phase III randomized study.
Clin Breast Cancer
; 1 Suppl 1: S15-8, 2000 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-11970744
Resultados
1 -
5
de 5
1
Próxima >
>>